EUVIMEDEUVIMED entdecken
Crossref

Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory

Elif Candan, Zeynep Ülker

Molecular Biology Reports · 2026-12 · 53 (1)

DOI: 10.1007/s11033-026-13052-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, online erschienen am 04.11.2026. Verfasst von Elif Candan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Istanbul University, Istanbul, Türkiye. Hauptthemen laut MEDLINE: Cisplatin, Luteolin, Flavonoids, Breast Neoplasms. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dietary flavonoids have been proposed as partners for platinum chemotherapy, but their effects vary between tumour types, and sparing of normal cells has to be demonstrated. We examined gossypetin and luteolin, alone and combined with cisplatin, in MCF-7 breast and HeLa cervical carcinoma cells and in non-tumorigenic L929 fibroblasts. METHODS AND RESULTS: Cells were exposed to 100 µg/mL cisplatin (CP), gossypetin (GOS), luteolin (LUT) or their double and triple combinations. Viability was measured by MTT assay (technical triplicates, one experiment), combination effects by Bliss independence, Bax, Bcl-2 and CASP3 transcripts by RT-PCR (2-ΔΔCt), and phosphatidylserine exposure by Annexin V-Cy3 staining of archived micrographs. At 48 h, six of the seven treatments reduced MCF-7 viability (61.8-85.0% of control; Tukey-adjusted p ≤ 0.018), gossypetin being the most active. Cisplatin plus luteolin exceeded the Bliss expectation in MCF-7 at 24 h (excess + 0.11), whereas all combinations were less than additive at 48 h. No treatment reduced HeLa viability, and HeLa cells showed Bcl-2 induction (1.9-30.2-fold) with Bax repression (Bax/Bcl-2 ratio 0.03-0.21). L929 viability was not reduced at either time point, and the archived L929 field showed no Annexin V labelling. CONCLUSIONS: At this single concentration, gossypetin- and luteolin-based treatments reduced MCF-7 viability without reducing L929 viability, while HeLa cells were refractory at the viability and transcript levels. These retrospective data support dose-response and protein-level studies rather than mechanistic conclusions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CisplatinLuteolinFlavonoidsBreast NeoplasmsUterine Cervical NeoplasmsHumansHeLa CellsFemaleMCF-7 CellsCell SurvivalApoptosisAnimalsAntineoplastic AgentsProto-Oncogene Proteins c-bcl-2bcl-2-Associated X ProteinMice

Stichwörter der Autor:innen

Bax/Bcl-2Breast cancerCisplatinDrug combinationGossypetinLuteolin

Substanzen

CisplatinLuteolinFlavonoidsAntineoplastic AgentsProto-Oncogene Proteins c-bcl-2bcl-2-Associated X Protein

Autor:innen und Institutionen

  • Istanbul University, Istanbul, Türkiye.
  • Department of Basic Sciences, Faculty of Dentistry, Istanbul Galata University, Istanbul, Türkiye. zeynep.ulker@galata.edu.tr.

Zitieren

APA

Candan, E., & Ülker, Z. (2026). Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular Biology Reports, 53(1). https://doi.org/10.1007/s11033-026-13052-7

Vancouver

Candan E, Ülker Z. Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory. Molecular Biology Reports. 2026;53(1). doi:10.1007/s11033-026-13052-7

BibTeX
@article{Candan2026,
  author = {Candan, Elif and Ülker, Zeynep},
  title = {Gossypetin and luteolin, alone and with cisplatin, preferentially reduce MCF-7 breast cancer cell viability, whereas HeLa cervical cancer cells are refractory},
  journal = {Molecular Biology Reports},
  year = {2026},
  volume = {53},
  number = {1},
  doi = {10.1007/s11033-026-13052-7}
}
Kostenlos starten →